Advertisement

Tumor Biology

, Volume 34, Issue 1, pp 359–368 | Cite as

ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder

  • Jinghe Li
  • Zhu-lin Yang
  • Xuebao Ren
  • Qiong Zou
  • Yuan Yuan
  • Lufeng Liang
  • Meigui Chen
  • Senlin Chen
Research Article

Abstract

Although the incidence of gallbladder cancers is low, they are highly aggressive tumors. Squamous cell/adenosquamous carcinoma (SC/ASC) is a rare subtype of gallbladder cancer. The clinical characteristics of SC/ASC have not been well documented, and no prognosis marker has been identified. In this study, we examined integrin-linked kinase (ILK) and peroxiredoxin-1 (PRDX1) expression in 46 SC/ASCs and 80 adenocarcinomas (ACs) by using immunohistochemistry and analyzed their correlations with clinicopathological characteristics. We demonstrated that positive ILK and PRDX1 expressions were significantly associated with large tumor size, high TNM stage, lymph node metastasis, and invasion of SC/ASC and AC. Univariate Kaplan–Meier analysis showed that positive ILK and PRDX1 expressions were closely associated with decreased overall survival in both SC/ASC (p < 0.001 and p = 0.005, respectively) and AC (p < 0.001) patients. Multivariate Cox regression analysis showed that positive ILK and PRDX1 expressions were an independent poor prognostic predictor in both SC/ASC and AC patients. We also revealed a similar significance of differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical curability with survival in SC/ASC and AC patients. Our study suggested that positive ILK and PRDX1 expressions are closely related to the progression and poor prognosis of gallbladder cancer.

Keywords

Gallbladder cancer Adenocarcinoma Squamous cell carcinoma Adenosquamous carcinoma ILK PRDX1 Prognosis Metastasis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin N Am. 2010;39:331–42.CrossRefGoogle Scholar
  3. 3.
    Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–81.PubMedCrossRefGoogle Scholar
  6. 6.
    de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg. 2006;10:186–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Durbin AD, Hannigan GE, Malkin D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle. 2009;8:4060–6.PubMedCrossRefGoogle Scholar
  9. 9.
    McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase—essential roles in physiology and cancer biology. J Cell Sci. 2008;121:3121–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRefGoogle Scholar
  11. 11.
    Watzka SB, Rauscher-Pötsch I, Stubenberger E, Getman V, Setinek U, Tötsch M, et al. Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg. 2010;38:254–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006;25:3237–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, et al. Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res. 2007;27:4371–6.PubMedGoogle Scholar
  14. 14.
    Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011;121:586–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMedGoogle Scholar
  16. 16.
    Neumann AC, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol. 2007;7:375–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997;11:2456–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 2002;277:43175–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156:27–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010;9:451–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008;14:2326–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMedGoogle Scholar
  24. 24.
    Liu DC, Yang ZL, Jiang S. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomark. 2010–2011;8:113–21.Google Scholar
  25. 25.
    Nishihara K, Nagai E, Izumi Y, et al. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res. 1994;85:389–99.PubMedCrossRefGoogle Scholar
  26. 26.
    Kondo M, Dono K, Sakon M, et al. Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 2002;49:1230–4.PubMedGoogle Scholar
  27. 27.
    Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRefGoogle Scholar
  28. 28.
    Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001;7:1987–91.PubMedGoogle Scholar
  29. 29.
    Prosperi MT, Ferbus D, Karczinski I, Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem. 1993;268:11050–6.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Jinghe Li
    • 1
  • Zhu-lin Yang
    • 2
  • Xuebao Ren
    • 2
  • Qiong Zou
    • 3
  • Yuan Yuan
    • 3
  • Lufeng Liang
    • 4
  • Meigui Chen
    • 5
  • Senlin Chen
    • 6
  1. 1.Department of Pathology, Basic School of MedicineCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Research Laboratory of Hepatobiliary Diseases, Second Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  3. 3.Department of Pathology, Third Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  4. 4.Department of Hepatobiliary and Pancreatic SurgeryHunan Provincial People’s HospitalChangshaPeople’s Republic of China
  5. 5.Department of PathologyLoudi Central HospitalLoudiPeople’s Republic of China
  6. 6.Department of PathologyHunan Provincial Tumor HospitalChangshaPeople’s Republic of China

Personalised recommendations